Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Arcutis today announced that management will participate in the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston.
-
Arcutis today reported financial results for the quarter and year ended December 31, 2025, and provided a business update.
-
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seb Derm to Speak with Their Healthcare Provider
-
WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
-
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a...
-
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
-
Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February...
-
Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Plans For Those With Chronic Inflammatory Skin Conditions
-
Arcutis today announced its strategic priorities for 2026.
-
Arcutis today announced that Amit Munshi has been appointed to its BOD, and announced the retirement of founder and Board member Bhaskar Chaudhuri, PhD.